The company recorded operating income of $0.9 million for the three-month period, compared to $2.7 million for the prior-year period. In the company’s Laboratory Segment, revenues from drugs-of-abuse
Centocor Ortho Biotech, a wholly-owned subsidiary of Johnson & Johnson, and Schering-Plough have announced that Health Canada has granted approval of Simponi as a once-monthly, subcutaneous therapy for
The research collaboration involves the preclinical application of ImmunoVaccine Technologies’s (IVT’s) DepoVax vaccine formulation to anthrax antigens to explore new methods to prevent, prepare for, and respond to
Biomet, a designer, manufacturer and marketer of products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy, has reported a net loss of $478.7m for
Core Essence Orthopaedics, a medical device company, has received 510k regulatory approval from the FDA for Securus, a novel knotless suture anchor system used in minimally invasive, arthroscopic
Azur will market Elestrin to estrogen prescribing physicians, comprised mostly of gynecologists. Azur recently increased its women’s health and urology sales force to 65 people to support the
The study has commenced recruiting patients in the US with sites in the UK, Germany and Australia due to open later in 2009. The OPTiM trial is a
“We are happy to report another quarter of excellent results and a very strong year filled with many accomplishments. We achieved record financial performance in 2008 with significant
The significant growth in revenues was due to an increase in sales of existing products in the growing China healthcare market, which included AMDL’s best-selling human placenta extract
Diluted earnings per share, excluding specified items, were $0.73, reflecting 15.9% growth, and $0.03 above the mid-point of Abbott’s previous first-quarter guidance range. Diluted earnings per share under
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.